Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

PeerView Oncology - Targeting HER2-Low Expression in Breast Cancer: Evaluating the Evidence, Challenges, and Opportunities for Expanding Treatment Benefit to More Patients

Exploring the Nuances of HER2-Targeted Treatment Selection for Patients With HER2-Low Breast Cancer: Expert Insights Into Implications for Practice and Team-Based Approaches to Individualizing Patient Care

Date

09 Sep 2022

Session

PeerView Oncology - Targeting HER2-Low Expression in Breast Cancer: Evaluating the Evidence, Challenges, and Opportunities for Expanding Treatment Benefit to More Patients

Topics

Patient Education and Advocacy;  Clinical Research;  Cancer Biology;  Cytotoxic Therapy;  Pathology/Molecular Biology;  Targeted Therapy;  Molecular Oncology;  Response Evaluation (RECIST Criteria)

Tumour Site

Breast Cancer

Presenters

Shanu Modi

Authors

A. Prat1, P. Tarantino2, S. Modi3

Author affiliations

  • 1 Medical Oncology Department, Hospital Clinic y Provincial de Barcelona, 08036 - Barcelona/ES
  • 2 Dana Farber Cancer Institute, 02215 - Boston/US
  • 3 Medicine, MSKCC - Memorial Sloan Kettering Cancer Center, 10065 - New York/US
More

Resources

Login to access the resources on OncologyPRO.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.